← Back to Clinical Trials
Recruiting Phase 4 NCT06270407

NCT06270407 The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06270407
Status Recruiting
Phase Phase 4
Sponsor St. Olavs Hospital
Condition Surgical Complication
Study Type INTERVENTIONAL
Enrollment 3,000 participants
Start Date 2024-10-01
Primary Completion 2028-12-31

Trial Parameters

Condition Surgical Complication
Sponsor St. Olavs Hospital
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 3,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-01
Completion 2028-12-31
Interventions
Tranexamic Acid 100 MG/ML0.9%sodium chloride

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Study objective: This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots. Eligible patients: Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery. Study intervention: Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.

Eligibility Criteria

Inclusion Criteria: * Patients are eligible to be included in the study only if all of the following criteria apply: 1. They are to undergo a surgical procedure within the field of plastic surgery where the procedure involves use of topical TXA at the participating center. 2. They are over 18 years of age and capable of independently providing informed consent 3. They have received adequate oral and written information about the study and signed the informed-consent form Exclusion Criteria: * Patients with known allergy to tranexamic acid. Insufficient knowledge of national language or English.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology